An observational study in Lenses, Intraocular, sponsored by Clínica Rementería. Completed at 1 site in Spain. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-03-18.
Sponsored by Clínica Rementería · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Astigmatism with a site in Spain — 2 open to participants now, 2 under way, none of them phase 3. Astigmatism · Spain.
Among the 16 studies in Astigmatism with a site in Spain, this one is one of 5 that started in 2021, is one of 4 observational ones, and was the 11th registered.
418 studies on the registry are indexed under Astigmatism; 51 are open to participants now.
Browse Astigmatism studies →2 of the 16 studies in Astigmatism with a site in Spain are open now. Recruiting first, the newest first:
CooperVision International Limited (CVIL) · Sites in Spain, United States
Ages 7–35
Biotech Healthcare Holding Gmbh · Sites in Spain, Germany, India
Ages 21+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 32 Astigmatism studies recruiting now, 12 (38%) set no upper age limit and 15 (47%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.
This study: 40 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 5 started in 2021.
This study's enrollment of 30 is below the median of 100 across 82 observational studies indexed under Astigmatism.
Median enrollment 60 across the 12 interventional studies, 39 across the 4 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 16 have an industry lead sponsor. The 10 most frequent:
Clínica Rementería is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Clínica Rementería has 1 study filed under Astigmatism — fewer than ten, so there is no comparison to draw.
2 of the studies in Astigmatism with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07751172CooperVision International Limited (CVIL)Evaluation of Orthokeratology Lenses With a 5MM Optic Zone Diameter | 2026-12 |
| NCT07232615Biotech Healthcare Holding GmbhA Planned Study at Multiple Sites is Being Done to Compare the Results of Two Types of Trifocal Toric Intraocular Lenses Used in Cataract Surgery | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Astigmatism with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Low amounts of postoperative residual astigmatism may worsen the visual performance of patients implanted with presbyopia- correcting intraocular lenses (IOLs). Although extended depth of focus (EDoF) IOLS have introduced optical improvements, it is important to determine the tolerance of these IOLs to postoperative astigmatism. This is important for an appropriate surgical planning.
Therefore, the aim of this study is to simulate and assess the impact of mild amounts of residual mixed astigmatisms with the axis oriented in different positions (vertical, oblique and horizontal) in eyes implanted with the Vivity® IOL.
Objectives:
Study Design: Prospective, single arm, descriptive, 3-month follow up.
Patient population: 30 consecutive eyes of 30 patients implanted with Vivity bilaterally with no postoperative complications. The calculation of the required sample size was based on monocular corrected distande visual acuity. A difference of 0.2 logMAR units was assumed to be clinically significant anda standard deviation of 0.05 was anticipated(data obtained from a comparative study between a bifocal and a trifocal IOL: Jonker SM, et al. Journal of Cataract Refract Surg. 2015; 41: 1631-40). Based on these assumptions, with an α of 0.05 and power of 0.8, it was calculated that 25 eyes were required in each group. Due to potential dropouts, a larger sample size has been selected.
Clinical Protocol: All patients fullfilling study criteria will be considered for inclusion three months after surgery. After patient consent, uncorrected distance visual acuity will be measured with an ETDRS chart, followed by subjective refraction (best distance correction). In all cases, mixed astigmatism will be induced with trial lens over the best distance corrected situation (considered the reference situation).
Once the best distance correction is determined, the different visual acuity evaluation procedures for this study will be performed with a Freiburg Acuity Test software package. The software will be run on a separate laptop screen calibrated to be presented at 4 meters. In this procedure, a black Landolt C is presented to the subjects and, among 8 different possibilities, they indicate the orientation of the optotype on a numeric keypad. This test minimizes the observer's bias because the presented optotype depends on the patient´s previous responses. That is, when the observer responds to a certain optotype, the software automatically modifies the size of the next optotype according to parameter estimation by a sequential test method. (7,8) Finally, all serious adverse events will be reported.
Statistical Analysis: Visual acuity values will be expressed as mean and standard deviation. Normal distribution of variables will be assessed using the Kolmogorov- Smirnov test. Pre- and post-operative data of each parameter will be compared by means of the Student's t-test. A repeated measure analysis of variance (ANOVA) will be used to gauge any statistically significant difference of the data within the different simulated situations. Differences are considered to be statistically significant for P value \<0.05 (i.e., at the 5% level).
Patients undergoing bilateral cataract surgery with bilateral Vivity intraocular lens implantation, with no other ocular diseases and no complications
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The study will include patients \>40 years old that undergo routine cataract surgery and implantation of Vivity ®. Exclusion criteria include corneal astigmatism ≥1.0 diopters (D ), amblyopia, previous ocular surgery and presence of ocular pathologies and abnormal iris. Patients with intra- or postoperative complications, with a postoperative best distance corrected visual acuity (BDCVA) \< 20/20 and with postoperative refractive astigmatism \> 0.50D will be also excluded . Inclusion and exclusion criteria will be assessed by an ophthalmologic examination including refraction, screening for ocular conditions and/or systemic diseases, slit-lamp biomicroscopy and fundus examination.
Device: Cataract surgery with Vivity intraocular lens implantation
Cataract surgery with Vivity intraocular lens implantation
Distance Against the Rule Astimatism
Change from baseline condition in the monocular best corrected distance visual acuity, inducing astigmatism of +0.25-0.50x0\*, taking as a reference the subjects' axis
Time frame: Three months after surgery
Distance Oblique Astigmatism
Change from baseline condition in the monocular best corrected distance visual acuity, inducing astigmatism of +0.25-0.50x45\*, taking as a reference the subjects' axis
Time frame: Three months after surgery
Distance With the Rule Astigmatism
Change from baseline condition in the monocular best corrected distance visual acuity, inducing astigmatism of +0.25-0.50x90\*, taking as a reference the subjects' axis
Time frame: Three months after surgery
| Milestone | Vivity Patients |
|---|---|
| Started | 30 |
| Completed | 30 |
| Not completed | 0 |
Change from baseline condition in the monocular best corrected distance visual acuity, inducing astigmatism of +0.25-0.50x0\*, taking as a reference the subjects' axis
| LogMAR | Vivity Patients |
|---|---|
| Distance Against the Rule Astimatism | 0.01 ± 0.04 |
Change from baseline condition in the monocular best corrected distance visual acuity, inducing astigmatism of +0.25-0.50x45\*, taking as a reference the subjects' axis
| LogMAR | Vivity Patients |
|---|---|
| Distance Oblique Astigmatism | 0.01 ± 0.06 |
Change from baseline condition in the monocular best corrected distance visual acuity, inducing astigmatism of +0.25-0.50x90\*, taking as a reference the subjects' axis
| LogMAR | Vivity Patients |
|---|---|
| Distance With the Rule Astigmatism | 0.01 ± 0.05 |
Collected over Three months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vivity Patients | 0/30 (0%) | 0/30 (0%) | 0/30 (0%) |
| Age, Continuous(years) | Vivity Patients |
|---|---|
| Mean | 69.37 ± 7.10 |
| Sex: Female, Male(Participants) | Vivity Patients |
|---|---|
| Female | 19 |
| Male | 11 |
| Race and Ethnicity Not Collected(Participants) | Vivity Patients |
|---|
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Data will be shared after reasonable request
Ran from Jun 2021 to primary completion in Mar 2022, 8 months.
Results were first posted in Mar 2024, 2 years after primary completion.
Of 35 observational studies under Astigmatism, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 92. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clínica Rementería